Days after the FDA approved Optinose’s nasal polyp drug, its commercialization will be the focus of a post-IPO spending spree.

The investment brings the total series A haul up to $46 million and equips Cambridge Medical Robotics to build on tests of its device on cadavers.

The series C tees SPR up to push a neurostimulation technology it wants to position as a drug-free way to relieve chronic and acute pain.

Notable Labs picked up $10 million for its service that helps identify combination treatments for blood cancer patients.

2016 was the year of the makeover. The top 10 medtech players are all in varying stages of transformation.

SetPoint Medical rounded up $30 million, which will bankroll a phase 2 trial of its bioelelectronic therapy for rheumatoid arthritis.

Alzeca Biosciences raised $11 million to develop its nanoparticle contrast agent, designed for the early detection of Alzheimer’s disease.

VentureMed Group raised $15 million to support R&D, clinical trials and expand the sales team for its PAD treatment catheter.